MX2014014350A - Nueva forma de dosificacion y formulacion de abediterol. - Google Patents

Nueva forma de dosificacion y formulacion de abediterol.

Info

Publication number
MX2014014350A
MX2014014350A MX2014014350A MX2014014350A MX2014014350A MX 2014014350 A MX2014014350 A MX 2014014350A MX 2014014350 A MX2014014350 A MX 2014014350A MX 2014014350 A MX2014014350 A MX 2014014350A MX 2014014350 A MX2014014350 A MX 2014014350A
Authority
MX
Mexico
Prior art keywords
abediterol
formulation
dosage form
inhalation
pharmaceutically acceptable
Prior art date
Application number
MX2014014350A
Other languages
English (en)
Inventor
Miquel Serra Gonzalo De
Ruiz Sandrine Allain
Nunez Beatriz Seoane
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014014350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2014014350A publication Critical patent/MX2014014350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona, una composición farmacéutica en forma de polvo seco para inhalación que comprende abediterol o una sal farmacéuticamente aceptable del mismo en mezcla con un excipiente inerte farmacéuticamente aceptable, que proporciona al ser inhalada una dosis equivalente a una dosis nominal medida de aproximadamente 1,25 o aproximadamente 2,5 de base libre abediterol administrada con el inhalador Genuair(r). La presente invención también proporciona dicha composición farmacéutica para uso en el tratamiento de una enfermedad respiratoria tal como asma y enfermedad pulmonar obstructiva crónica EPOC.
MX2014014350A 2012-05-31 2013-05-30 Nueva forma de dosificacion y formulacion de abediterol. MX2014014350A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382221.5A EP2668941A1 (en) 2012-05-31 2012-05-31 Novel dosage form and formulation of abediterol
US201261660003P 2012-06-15 2012-06-15
PCT/EP2013/061181 WO2013178742A1 (en) 2012-05-31 2013-05-30 Novel dosage form and formulation of abediterol

Publications (1)

Publication Number Publication Date
MX2014014350A true MX2014014350A (es) 2015-03-03

Family

ID=46317311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014350A MX2014014350A (es) 2012-05-31 2013-05-30 Nueva forma de dosificacion y formulacion de abediterol.

Country Status (29)

Country Link
US (2) US20150140099A1 (es)
EP (2) EP2668941A1 (es)
JP (1) JP6272836B2 (es)
KR (2) KR20150018526A (es)
CN (1) CN104394852A (es)
AR (1) AR091233A1 (es)
AU (1) AU2013269565B2 (es)
BR (1) BR112014029735A2 (es)
CA (1) CA2871358C (es)
CL (1) CL2014003286A1 (es)
CO (1) CO7141434A2 (es)
CR (1) CR20140540A (es)
DO (1) DOP2014000271A (es)
EA (1) EA201401354A1 (es)
EC (1) ECSP14028814A (es)
HK (1) HK1203149A1 (es)
IL (1) IL235831B (es)
IN (1) IN2014DN08672A (es)
MX (1) MX2014014350A (es)
MY (1) MY184654A (es)
NI (1) NI201400139A (es)
NZ (1) NZ701261A (es)
PE (1) PE20150171A1 (es)
PH (1) PH12014502662A1 (es)
SG (3) SG10201609119VA (es)
TW (1) TWI610690B (es)
UY (1) UY34838A (es)
WO (1) WO2013178742A1 (es)
ZA (1) ZA201407405B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20150224197A1 (en) * 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2015193631A1 (en) * 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2019226697A1 (en) 2018-05-22 2019-11-28 C.R. Bard, Inc. Catheterization system and methods for use thereof
JP7314252B2 (ja) 2018-08-10 2023-07-25 シー・アール・バード・インコーポレーテッド 自動尿量測定システム
US11931151B2 (en) 2020-12-22 2024-03-19 C. R. Bard, Inc. Automated urinary output measuring system

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
WO1992004928A2 (en) 1990-09-26 1992-04-02 Pharbita B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
HU215510B (hu) 1992-12-18 1999-01-28 Schering Corp. Inhalátor por alakú gyógyszerekhez
PT837710E (pt) 1995-06-21 2002-05-31 Sofotec Gmbh & Co Kg Cartucho de po farmaceutico com dispositivo de doseamento integrado e inalador para medicamentos em po
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
DE602005023690D1 (de) 2004-07-16 2010-11-04 Almirall Sa Inhalator für die Abgabe von pharmzeutischen Pulver, und ein Pulverkassette zur Verwendung mit diesem Inhalator
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases

Also Published As

Publication number Publication date
EA201401354A1 (ru) 2015-05-29
AU2013269565A1 (en) 2014-10-30
JP2015519356A (ja) 2015-07-09
KR20180104197A (ko) 2018-09-19
EP2668941A1 (en) 2013-12-04
MY184654A (en) 2021-04-14
US20150140099A1 (en) 2015-05-21
JP6272836B2 (ja) 2018-01-31
CR20140540A (es) 2015-01-16
UY34838A (es) 2014-03-31
SG10201609119VA (en) 2016-12-29
ECSP14028814A (es) 2015-12-31
EP2854771A1 (en) 2015-04-08
SG11201407110QA (en) 2014-12-30
AU2013269565B2 (en) 2017-07-20
PH12014502662A1 (en) 2015-02-02
IL235831B (en) 2020-09-30
US20160303108A1 (en) 2016-10-20
CL2014003286A1 (es) 2015-02-20
CN104394852A (zh) 2015-03-04
DOP2014000271A (es) 2015-02-27
BR112014029735A2 (pt) 2017-06-27
CA2871358A1 (en) 2013-12-05
SG10201913424SA (en) 2020-03-30
TW201347789A (zh) 2013-12-01
WO2013178742A1 (en) 2013-12-05
ZA201407405B (en) 2015-11-25
HK1203149A1 (en) 2015-10-23
IN2014DN08672A (es) 2015-05-22
IL235831A0 (en) 2015-01-29
KR20150018526A (ko) 2015-02-23
PE20150171A1 (es) 2015-01-31
TWI610690B (zh) 2018-01-11
NI201400139A (es) 2015-12-10
NZ701261A (en) 2016-08-26
CO7141434A2 (es) 2014-12-12
CA2871358C (en) 2020-09-29
AR091233A1 (es) 2015-01-21

Similar Documents

Publication Publication Date Title
UA101653C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
EA201590030A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
JO3024B1 (ar) صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TH1401007107A (th) รูปฟอร์มขนาดใช้ยา และ สูตรผสมใหม่ของเอบีไดเทอรอล
GR1008468B (el) Μιγμα σισπλατινης σε μορφη λεπτοκοκκης εισπνεομενης ξηρας σκονης
BR112014028864A2 (pt) dosagem e formulação